Informed Momentum Co LLC Decreases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Key Points

• Informed Momentum Co LLC has reduced its holdings in Tarsus Pharmaceuticals by 27%, now owning 52,413 shares worth approximately $2.69 million.
• Several institutional investors increased their stakes in Tarsus Pharmaceuticals during the fourth quarter, with Toronto Dominion Bank acquiring a new stake worth $105.71 million.
• Analyst ratings for Tarsus Pharmaceuticals are generally positive, with a mix of upgrades and a current average target price of $66.67, reflecting a "Moderate Buy" consensus.

Informed Momentum Co LLC reduced its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 27.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,413 shares of the company's stock after selling 19,402 shares during the quarter. Informed Momentum Co LLC owned 0.12% of Tarsus Pharmaceuticals worth $2,692,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TARS. Toronto Dominion Bank purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter worth approximately $105,714,000. Lord Abbett & CO. LLC grew its stake in Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after buying an additional 685,111 shares during the period. Millennium Management LLC grew its stake in Tarsus Pharmaceuticals by 189.4% during the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company's stock worth $35,659,000 after buying an additional 421,495 shares during the period. Gilder Gagnon Howe & Co. LLC grew its stake in Tarsus Pharmaceuticals by 5,636.3% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 404,237 shares of the company's stock worth $22,383,000 after buying an additional 397,190 shares during the period. Finally, Nuveen LLC purchased a new stake in Tarsus Pharmaceuticals during the first quarter worth approximately $13,589,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research note on Tuesday, May 27th. Guggenheim upped their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an "outperform" rating and a $75.00 target price for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $66.67.

Tarsus Pharmaceuticals Trading Up 2.6%

TARS opened at $51.36 on Wednesday. The stock has a market capitalization of $2.17 billion, a PE ratio of -22.04 and a beta of 0.79. The firm's fifty day moving average price is $41.82 and its 200 day moving average price is $45.71. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. Tarsus Pharmaceuticals, Inc. has a 12-month low of $24.95 and a 12-month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.15). The company had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. As a group, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.